Lau, Sally C. M.
Batra, Ullas
Mok, Tony S. K.
Loong, Herbert H.
Funding for this research was provided by:
Pfizer
Article History
First Online: 8 May 2019
Compliance with Ethical Standards
:
: Funding for editorial support for styling the article was provided by Pfizer.
: Sally C. M. Lau and Ullas Batra have no conflicts of interest that are directly relevant to the content of this article. Tony Mok has received consulting fees/honorarium from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Inc., Vertex Pharmaceuticals, BMS, OncoGenex Pharmaceuticals, Inc., Celgene, Ignyta, Inc., Fishawack Facilitate Ltd, Takeda Oncology, Janssen, Hutchison Chi-Med, OrigiMed, Hengrui Therapeutics Inc., Sanofi-Aventis, R&D, Yuhan Corporation, PrlME Oncology, Amoy Diagnostics Co., Ltd., and Loxo-Oncology. He has also received payment for lectures including speakers’ bureaus from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, MSD, Novartis, BMS, Taiho, Takeda Oncology, PrlME Oncology, and Amoy Diagnostics Co., Ltd. He has held or currently holds stock/stock options in Sanomics Ltd. and Hutchison Chi-Med. Herbert H. Loong has received research funding from MSD and Mundipharma. He has also served or is currently serving on the advisory boards of Boehringer Ingelheim, Eli Lilly, Novartis, LOXO Pharmaceuticals, and Roche/Genentech. He has received speakers’ fees from AbbVie, Bayer, Eisai Pharmaceuticals, Eli-Lilly, Guardant Health, and Novartis.